Histogen Inc (HSTO)
0.3501
0.00 (0.00%)
USD |
OTCM |
Apr 24, 10:56
Histogen Net Income (TTM): -12.38M for Sept. 30, 2023
Net Income (TTM) Chart
Historical Net Income (TTM) Data
Date | Value |
---|---|
September 30, 2023 | -12.38M |
June 30, 2023 | -12.12M |
March 31, 2023 | -13.42M |
December 31, 2022 | -10.62M |
September 30, 2022 | -10.79M |
June 30, 2022 | -11.04M |
March 31, 2022 | -11.35M |
December 31, 2021 | -14.95M |
Date | Value |
---|---|
September 30, 2021 | -15.32M |
June 30, 2021 | -14.73M |
March 31, 2021 | -21.20M |
December 31, 2020 | -18.77M |
September 30, 2020 | -17.57M |
June 30, 2020 | -16.02M |
March 31, 2020 | -9.747M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (TTM) Range, Past 5 Years
-21.20M
Minimum
Mar 2021
-9.747M
Maximum
Mar 2020
-14.00M
Average
-13.42M
Median
Mar 2023
Net Income (TTM) Benchmarks
CEL-SCI Corp | -31.05M |
AIM ImmunoTech Inc | -28.96M |
IGC Pharma Inc | -14.14M |
NovaBay Pharmaceuticals Inc | -9.64M |
Protalix BioTherapeutics Inc | 8.312M |